Complete Genomics: Faster more accurate sequencing technology

Options
jenrio
jenrio Member Posts: 558
edited June 2014 in Clinical Trials, Research News, Podcasts, and Study Results

http://www.reuters.com/article/2012/07/12/us-completegenomics-shares-idUSBRE86B0PQ20120712

http://www.completegenomics.com/public-data/cancer-data/

http://www.completegenomics.com/services/cancer/

http://www.completegenomics.com/news-events/press-releases/Complete-Genomics-Announces-New-Technology-Developed-to-Set-Standard-for-Clinical-Grade-Genomes-161946595.html

Quote:  

"The Nature paper by Peters et al. describes how our LFR technology uses ‘barcoded' DNA to generate whole genome sequencing with approximately one error in 10 million base pairs, or just 600 errors in an entire human genome," said Dr. Rade Drmanac, the company's chief scientific officer and inventor of the LFR technology. "This represents a 10-fold increase in accuracy for Complete and is unmatched by any high-sensitivity method currently available."
 

In addition, Complete's LFR technology provides, for the first time, accurate whole-genome sequencing from as few as 10 to 20 cells (only 100 picograms of DNA), making it an ideal choice for small sample clinical sequencing applications including circulating tumor cells, fine needle aspirations, and pre-implantation genetic diagnostics 

More quotes:Gene sequencing companies, which also include bigger names Illumina Inc and Life Technologies Corp, cater to a client base that mostly comprise educational and research institutions and compete on price.

The sector has recently come under pressure from a cut in the funding provided by the National Institutes of Health (NIH) for basic science research.

As the technology is yet to see widespread commercial adoption, the funding cut is one of the biggest issues faced by the sector that is on a persistent drive to bring down the price of gene sequencing to about $1,000.

Currently, the average price is $4,000-$5,000.

My take:  This price is affordable for some patients.  Comparible to the $2000 charged by Oncotype DX, and BRCA testing and others, generate a lot more information.   What's not to like?

· Share on FacebookShare on Twitter

Comments

  • mkkjd60
    mkkjd60 Member Posts: 583
    edited July 2012

    Jenrio, First I want to thank you for your posts.  I read them every day.  My mom is stage iv bc.  She is 72.  What is your opinion on the info that could be generated by such sequencing?  I would gladly pay for it for my mom. Thanks again. Mary

    · Share on FacebookShare on Twitter
  • jenrio
    jenrio Member Posts: 558
    edited July 2012

    A lot of information, not as much as we'd like, but its accuracy and how little sample it takes (CTC) is a big sell for me. 

    Some types of BC has tumor mutations that are not standard BC, more like standard other cancer, which may have well targetted drugs for them.       It could perhaps help your onco find a better targetted 2nd/3rd/4th line chemo/biological and gave the patient valuable time with better tolerance.   It could give researchers more insight on why you are or are not responding to certain treatment or become resistant.   It could in future change the way clinical trials are run and lead to the cure.   Faster, more accurate, cheaper.  

    So my Cato bit:  support research, support clinical trials to find the MBC cure.   Note the NIH funding cut, the public needs to invest more money into basic science, better technologies and finding the cure, and spend less money on expensive tests/procedures/drugs/charities that really don't deliver the bang for the buck.

    · Share on FacebookShare on Twitter

Categories